OmniAb (OABI) Amortization - Intangibles (2022 - 2026)
OmniAb (OABI) posted quarterly Amortization - Intangibles of $6.0 million for Q1 2026, up 88.38% year-over-year from $3.2 million in Q1 2025, and up 88.38% quarter-over-quarter from $3.2 million in Q4 2025.
Analysis
OmniAb (OABI) Amortization - Intangibles (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Amortization - Intangibles for 5 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 88.38% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $15.7 million (down 8.99% YoY), while the FY2025 annual figure was $12.9 million, down 25.89% from the prior year.
- Amortization - Intangibles improved to $6.0 million in Q1 2026 per OABI's latest filing, from $3.2 million in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $6.1 million in Q4 2024 and bottomed at $3.1 million in Q2 2022.
- Historically, Amortization - Intangibles has averaged $3.7 million across 5 years, with a median of $3.4 million in 2023.
- Annual changes were most pronounced in 2025 — Amortization - Intangibles tumbled 47.19% — and 2026, when it surged 88.38%.
- OmniAb's Amortization - Intangibles stood at $3.3 million in 2022, then grew by 5.43% to $3.5 million in 2023, then surged by 75.42% to $6.1 million in 2024, then sank by 47.19% to $3.2 million in 2025, then soared by 88.38% to $6.0 million in 2026.
- Business Quant data shows OABI's Amortization - Intangibles at $6.0 million in Q1 2026, $3.2 million in Q4 2025, and $3.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | OmniAb | 582.15 Mn | 530.16 Mn | 12.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.10 Mn |
| Mar 31, 2026 | 6.03 Mn |
| Dec 31, 2025 | 3.21 Mn |
| Sep 30, 2025 | 3.23 Mn |
| Jun 30, 2025 | 3.23 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Sep 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 3.45 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.40 Mn |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 3.30 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 3.41 Mn |